Medline ® Abstract for Reference 74
of 'Overview of paraneoplastic syndromes of the nervous system'
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes.
Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van 't Veer M, Sillevis Smitt P
J Neurol. 2006;253(1):16.
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved>or =1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.
Dept. of Neurology, Erasmus MC, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.